{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:44:03Z","timestamp":1766382243011,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>&amp;#9660Sibutramine* (Reductil - Abbott Laboratories), an orally active monoamine re-uptake inhibitor, is marketed in the UK for treating overweight adults. The company claims that it \"helps obese patients control their eating\". Is the drug worth prescribing?<\/jats:p>","DOI":"10.1136\/dtb.2001.391289","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"89-91","source":"Crossref","is-referenced-by-count":3,"title":["Is \u25bcsibutramine more than a slim hope?"],"prefix":"10.1136","volume":"39","member":"239","published-online":{"date-parts":[[2001,12,1]]},"reference":[{"key":"2025082703005487000_39.12.89.1","unstructured":"National Audit Office. Tackling obesity in England . London: The Stationery Office. Available: http:\/\/www.nao.gov.uk [February 2001]."},{"key":"2025082703005487000_39.12.89.2","doi-asserted-by":"crossref","unstructured":"Williamson D F et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128-41.","DOI":"10.1093\/oxfordjournals.aje.a117386"},{"key":"2025082703005487000_39.12.89.3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.ijo.0801687","article-title":"The Swedish Obese Subjects (SOS) study-rationale and results.","volume":"25","author":"Torgerson","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2025082703005487000_39.12.89.4","doi-asserted-by":"crossref","unstructured":"Why and how should adults lose weight? DTB 1998; 36: 89-92.","DOI":"10.1136\/dtb.1998.361289"},{"key":"2025082703005487000_39.12.89.5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","article-title":"Sibutramine: a review of its contribution to the management of obesity.","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"2025082703005487000_39.12.89.6","doi-asserted-by":"crossref","unstructured":"Hansen DL et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23: 1016-24.","DOI":"10.1038\/sj.ijo.0801059"},{"key":"2025082703005487000_39.12.89.7","unstructured":"Reductil . Summary of product characteristics, UK Knoll Ltd, May 2001."},{"key":"2025082703005487000_39.12.89.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss.","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"2025082703005487000_39.12.89.9","first-page":"505","article-title":"Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.","volume":"50","author":"Smith","year":"2001","journal-title":"J Fam Pract"},{"key":"2025082703005487000_39.12.89.10","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial","volume":"356","author":"James","year":"2000","journal-title":". Lancet"},{"key":"2025082703005487000_39.12.89.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"2025082703005487000_39.12.89.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00411-2"},{"key":"2025082703005487000_39.12.89.13","doi-asserted-by":"crossref","unstructured":"Failings in treatment advice, SPCs and black triangles. DTB 2001; 39: 25-7.","DOI":"10.1136\/dtb.2001.39425"},{"key":"2025082703005487000_39.12.89.14","unstructured":"National Institute for Clinical Excellence. Guidance on the use of sibutramine for the treatment of obesity in adults . Technology Appraisal Guidance - No. 31. Available: http:\/\/www.nice.org.uk [October 2001]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2001.391289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:01:06Z","timestamp":1756288866000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2001.391289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2001,12,1]]},"published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1136\/dtb.2001.391289"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2001.391289","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}